| Proposed Ticker: PGEN | 1507 Chambers Road | |
| Exchange: NASDAQ-National Market | Columbus, Ohio 43212 | |
| Industry: Manufacturing | (614) 488-6688 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 6/6/96 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $11.00 - $13.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 2,500,000 | Expenses: | - | |
| Secondary Shares: | 0 | Shs Out After: | 7,293,819 | |
| Spin out parent firm: | Interneuron Pharmaecuticals, Inc. | |||
| Manager | Tier | Phone |
| Vector Securities International, Inc. | Lead Manager | (708) 940-1970 |
| Genesis Merchant Group Securities | Co-manager | (800) 833-6482 |
| Tucker Anthony Incorporated | Co-manager | (617) 725-2000 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 9/30/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $2.82 | $0.91 | $0.01 | Assets: | $1.09 |
| Net Income: | -$2.88 | -$1.54 | -$2.49 | Liabilities: | $2.38 |
| EPS: | Equity: | -$1.29 | |||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a functional genomics company engaged in the discovery, characterization and validation of novel genes, receptors and related proteins as therapeutic leads and targets for the treatment of major diseases. The company's functional genomics approach combines developmental biology expertise and proprietary technology with gene sequencing and other molecular biology techniques to accelerate the discovery process. Using its developmental biology approach to functional genomics, the company has made several discoveries, including the discovery of the B219 leptin receptor, for which it filed patent applications in September and December 1994. Leptin is believed to have roles in blood cell formation, reproduction and obesity. The company has entered into a collaboration with Chiron Corporation for the development and commercialization of the company's proprietary gene delivery system, and collaboration with Novo Nordisk A/S for the isolation, development and commercialization of blood cell growth factors. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used to fund research and development activities, to fund expansion of facilities and acquisition of equipment, and for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.